Analysis of seroprevalence in target wildlife during the oral rabies vaccination programme in Lithuania

Dainius Zienius¹*, Janina Mickutė¹, Arnoldas Pautienius¹, Juozas Grigas¹, Arunas Stankevičius¹, Gediminas Pridotkas², Eugenijus Jacevičius², Jolita Kemeraitė² and Ingrida Jacevičienė²

Abstract

Background: Rabies vaccination of wildlife carnivores is a powerful tool to prevent, control and eliminate rabies. The presence of neutralizing rabies antibodies in blood is considered a reliable indicator of adequate vaccination. The main purpose of the present study was to analyze the seroprevalence of specific antibodies in target populations of Lithuanian red fox (RF) and raccoon dog (RD) during the oral rabies vaccination (ORV) campaigns during the 2010–2019 period.

Results: Over the ten-year period, 7,261 RF and 2,146 RD sera samples were collected post-mortem in field conditions and tested using a commercial standardized enzyme-linked immunosorbent assay (ELISA) kit in Lithuania. In the ORV spring and autumn vaccination periods, 31.8% (20.3–43.4 95% CI – 95% confidence interval) and 31.7% (21.2–42.1 95% CI) of RF, and 34.1% (22.5–45.7 95% CI) and 34.7% (22.7–46.7 95% CI) of RD sera samples, respectively, were identified as ELISA-positive (seroconversion ≥ 0.5 EU/mL—Equivalent Units per Millilitre). The seroprevalence analysis in adult/juvenile animal subpopulations indicated that 34.9% (27.2–42.5 95% CI) and 29.2% (20.3–37.9 95% CI) of RF, and 35.6% (25.2–46.0 95% CI) and 30.6% (20.2–40.9 95% CI) of RD sera samples, respectively, were identified as ELISA-positive (seroconversion ≥ 0.5 EU/mL). Statistically strong determinate correlations (r) between the serological results (pos.%) in RF adult/juvenile animal subpopulations (r = 0.937) and between RF and RD positive seroconvert (pos.%) sera samples during the spring vaccinations (r = 0.864) were demonstrated. In different ORV periods, 14–29% of RF and 7–25% of RD sera samples were identified as ELISA-negative (seroconversion < 0.5 EU/mL), but with low (0.125 < 0.49 EU/mL) antibody (Abs) titres.

Conclusions: The 2010–2019 ORV programme has been an effective tool in both RF and RD populations in Lithuania. The rabies-free status of Lithuania was self-declared in 2015 with only three rabies cases identified in buffer zones since then. The percentage of ELISA-positive serum samples (seroconversion ≥ 0.5 EU/mL) during the different periods of vaccination was similar in RF and RD populations—32% and 34% respectively. The identified seroconversion average of 21.5% in RF and 16% in RD sera samples were officially identified as ELISA-negative (seroconversion < 0.5 EU/mL), but with low (0.125 < 0.49 EU/mL) antibody (Abs) titres. That low, but positive seroconversion participated in the formation of populations overall immune status and can influence the interpretation of oral vaccination efficacy.

Keywords: Rabies, Lithuania, Raccoon dog, Red fox, ELISA, Seroconversion, Vaccination
relatively susceptible to the classical strains of rabies virus (RV) in Europe and constitute a possible inter-species transfer pathway in the wild [1]. A long-term retrospective study of the rabies epidemiological status in wildlife in eastern and northern regions of Europe identified that rabies-positive cases have been observed mainly in RF and RD [2, 3]. The involvement of two alternative rabies vectors in the epidemiological chain has challenged health authorities and cast doubts on the success of the traditional method of oral rabies vaccination (ORV), which has been used successfully to control rabies (targeting RF) in western Europe [4]. However, a retrospective analysis of ORV programmes has shown that despite the adaptive capacity of rabies viruses and the potential for inter-species transmission, this natural infection can be controlled in wildlife using the classic control tool of oral vaccination [5]. Therefore, with financial support from the European Union (EU), ORV programmes are currently being implemented in regions of 12 EU member states (including the Baltic countries), as well as in neighboring countries such as Russia, Ukraine, Belarus and the Western Balkans [4, 6].

Almost all the ORV campaigns that have been carried out are being monitored and their effectiveness in field conditions evaluated. These studies are being conducted under national programmes for the control of effectiveness of rabies vaccination and are based on direct and indirect assessment methods, including quantitative testing of oral vaccine bait distribution in target populations (bait uptake), evaluation of post-vaccination immunological status (seroprevalence in target species), and epidemiological studies of rabies positive/negative cases in wildlife (post-vaccination period) [6, 7].

Detection of rabies virus neutralizing antibodies (Abs) is one of the key factors in determining successful vaccination [8, 9], leading to a positive evaluation of rabies vaccination efficacy [10, 11]. The World Health Organization [12] and the World Organization for Animal Health [13] recommend two reference methods that allow quantification of specific neutralizing Abs against RV [14, 15]: the fluorescent antibody virus neutralization test (FAVN) [16] and the rapid fluorescent focus inhibition test (RFFIT) [17]. Both methods have been used for a considerable time in rabies reference laboratories as a gold standard in the measurement of Abs. They are of sufficient quality and reliability because they are based on the classic seroneutralization of live RV in sensitive cell systems. Nevertheless, both methods are relatively expensive, take a long time to complete, and require highly specialized laboratory technicians and high biosecurity-level implementation. Moreover, methods are based on susceptible cell cultures and the success of testing is highly dependent on the quality of the test samples, which may contain cytotoxic substances and contaminants that directly influence the sensitivity, quality and prognosis of the methods [18, 19]. This is especially true when it comes to measuring the effectiveness of ORVs in wildlife and using serological testing of field samples, which are classified as “body fluids” rather than clean sera samples.

Therefore, to assess the status of rabies post-vaccination immunity in the field, a new serological assay was required that was better suited to poor-quality, haemolysed, relatively cytotoxic and potentially contaminated wildlife specimens [20]. Thus, a method significantly less sensitive to external factors for rabies serological testing—the enzyme-linked immunosorbent assay (ELISA)—has been proposed. ELISA is quick and easy to perform, allowing for large-scale testing which is particularly important for controlling the effectiveness of ORV programmes. This method is not subject to strict biosafety requirements because live RV and sensitive cell cultures are not used to perform the test [21]. ELISA has repeatedly been used to detect rabies-specific Abs in domestic/wild animal sera samples of different biological quality, and can be considered as one of the most acceptable methods for monitoring the efficacy of ORV campaigns in foxes for avoiding cytotoxicity problems [6, 18, 22, 23]. Bio-Rad (Marnes-La-Coquette, France) developed an ELISA kit (Platelia™ Rabies II kit ad usum veterinarium) for serum samples of domestic and wild carnivores over twelve years ago. The method was approved by ANSES Nancy Laboratory [24] and evaluated before marketing [22]. Eight EU countries running national ORV programmes have adopted an ELISA to evaluate vaccine effectiveness in wildlife [6]. These investigations reveal high variability in serological results, with a specific antibody response ranging from 17 to 82% [6]. Varying investigation results have initiated a broad scientific debate on evaluation of the efficacy of post-vaccine immunity status and the priorities for the control of oral vaccination programmes in wildlife.

The objective of the present study was to analyze the status of seroconversion of Lithuanian ORV campaigns during the 2010–2019 period using seroprevalence studies of rabies-specific Abs in RD and RF sera samples collected from vaccination areas in the field.

Methods

ORV
Oral vaccination of wild animals against rabies using baits with attenuated vaccine started in 2006 and has been systematically carried out in Lithuania according to the classic scheme of bait distribution [25–27]. In the 2006–2015 period, spring (March–May) and autumn (October–December) ORV campaigns were carried out
in wildlife throughout the country (65,000 km²). Vaccine baits were dropped from aircraft manually and using mechanical devices, with an average concentration of 20 baits/km² in all RF and RD inhabited areas. Given that the 2006–2015 ORV programme in Lithuania was effective and the epidemiological situation of rabies improved, since the spring of 2016 vaccinations have been carried out according to the new programme approved by the European Commission [5]. Under this programme, vaccine baits have not been used throughout Lithuania, but are only distributed at its borders (buffer zones) with neighboring countries: the Kaliningrad region of the Russian Federation, Poland and Belarus. Thus in line with the newly implemented Programme for Rabies eradication submitted for obtaining EU co-financing, in the 2016–2019 period, spring (March–May) and autumn (October–December) ORV campaigns were carried out in wildlife in the buffer zones with neighboring countries (Fig. 3). 1,715,000 vaccine baits were distributed every year in the 35,300 km² vaccination area. To increase the effectiveness of the programme, vaccine baits in these areas have been thrown at twice the density – with an average concentration of 48 baits/km² in all the selected RF and RD inhabited areas.

**Vaccine**

LYSVULPEN (Bioveta A.S., Czech Republic) live attenuated RV vaccine (SAD-Bern strain, biological activity 1.8 × 10⁶ TCID₅₀/bait; TCID – tissue culture infective dose) was used in ORV programmes in Lithuania in the periods 2006–2010 and 2013–2019. During the 2011–2012 ORV program FUCHSORAL (IDT Biologika GmbH, Germany) vaccine (live SAD B19 strain with biological activity 10⁶ FFU/mL; FFU—focus forming units) was used in Lithuania. Vaccines were stored according to the instruction manuals in refrigerators at/below −20 °C before use and throughout the vaccination campaigns.

**Sample collection**

To evaluate the effectiveness of ORV campaigns, recommended sampling schemes (EFSA/WHO) in vaccination regions were used, taking into account the investigation of post-vaccination seropositive status in target populations [7, 12, 28, 29]. For rabies-specific antibody seroprevalence testing, samples of target animals (RF and RD) were collected throughout the ten-year period, covering the country’s entire territory and at all stages of oral vaccination, regardless of the vaccination period. The RF and RD serum samples were collected under field conditions throughout the all-year hunting periods and evaluated in two time-interval categories. Samples collected during January-June and during July-December were tested and evaluated as spring (S) ORV and as autumn (A) ORV samples, respectively. Of the samples tested, 80% were from hunted animals, about 15% were from animals found dead in the wild, and the remaining 5% were from animals that had died of other causes. Target blood samples (blood clots, thoracic transudates) were collected under field conditions directly from the chest cavity and placed in a refrigerator at +4 °C for 24 h. Sera samples were inactivated (30 min at 56 ± 2 °C) and stored at −20 °C until testing. All the collected samples (independent of their quality) were analyzed for specific rabies Abs by ELISA at the National Food and Veterinary Risk Assessment Institute of Lithuania (NFVRAI).

**ELISA**

Commercial standardized ELISA kits (Platelia™ Rabies II kit *ad Isum Veterinarium*, Bio-Rad, France) were used for RV-specific Abs detection and titre evaluation of blood sera samples from animals. An assay was performed in a standard 96-well microplate coated with RV glycoprotein, as previously described [24] and according to the manufacturer’s instructions. Briefly, diluted (1/100) samples (100 µL), calibrated positive controls (PC) or quantitative standards (S1–S6) in duplicates were distributed in microplate wells and incubated for 1 h at 37 ± 2 °C. After washing (3 ×), conjugate (100 µL, Protein A-peroxydase) was added and incubated for 1 h at 37 ± 2 °C. Following incubation, microplate washings were performed again (5 ×), the substrate (100 µL of TMB chromogen solution) was added, and the microplate was incubated in the dark at room temperature for 30 ± 5 min. After that, blocking solution (100 µL, H₂SO₄ sol.) was added to the microplate wells to stop the reaction. Optical density (OD) was measured using an automatic microplate analyzer (spectrophotometer) Elx808 (Bio-Tek, USA) at 450 nm wavelength. The positivity threshold was determined using control sera provided with the diagnostic kit. The standard curve was established using the OD values obtained for each quantification standard (S1–S6) according to the manufacturer’s instructions. Antibody titres in quantitative assays were obtained after direct reading of the standard curve and expressed in equivalent units per millilitre (EU/mL), which was calculated using the standard linear regression method. Results were evaluated when the negative control OD value was less than 0.05, the R4a positive control OD value was between 0.300 and 1.200, and the R4b positive control OD value was between 1.500 and 3.500. The threshold was the mean of two R4a positive controls (OD R4a) and corresponded to a protective value of 0.5 EU/mL [4, 9, 28, 30]. The high protection value equaled the average of two R4b positive controls (OD R4b). The optical density of each sample was compared with the high protection and threshold values. The seroconversion
rate of the ELISA test samples was identified in four categories depending on the determined Abs titres: negative (< 0.125 EU/mL); low (0.125 < 0.49 EU/mL), standard (0.5 ≤ 2 EU/mL) and high (> 2 EU/mL). The laboratory test results from all these different seroconversion groups were used for statistical analysis.

**Statistical analysis**
Statistical data analysis was performed using IBM SPSS Statistics Base (IBM, USA). Statistical calculations of positive (Abs titers of 0.5 ≤ 2 EU/mL and > 2 EU/mL) and negative (Abs titer < 0.125 EU/mL and 0.125 < 0.49 EU/mL) ELISA samples (n/%) were reported. General statistical accounting methods were used and mean (M), minimum and maximum values (Min/Max), average standard deviation (±SD) and 95% confidence interval (95% CI) were counted for data analysis and interpretation. One-Way ANOVA procedure and Post Hoc Multiple Comparisons types of tests for comparing M was used. Tukey’s significant difference range statistic tests for multiple pair wise comparisons between groups were chosen. The comparative statistical analyses were performed in each study category: RF and RD populations, juvenile and adult subpopulations, spring and autumn vaccination periods. To evaluate the association between different categories rank orders the Bivariate Correlations procedure was used, Spearman correlation coefficient (r) was calculated and analyzed using a confidence factor (p).

**Results**
During the 2010–2019 ORV programme, 2,214 of 6,345 (34.9%) tested adult RF (27.2–42.5 95% CI; Additional file 1) and 641 of 1,800 (35.6%) tested adult RD (25.2–46.0 95% CI Additional file 2) sera samples were ELISA-positive (seroconversion ≥ 0.5 EU/mL; Fig. 1a). The same investigation in a category of young animals showed 266 of 916 (29.2%) tested juvenile RF (20.3–37.9 95% CI; Additional file 1) and 106 of 346 (30.6%) tested juvenile RD (20.2–40.9 95% CI; Additional file 2) were identified as ELISA-positive (Fig. 1a). Annual immunization rates (pos.%; Fig. 1a) in the adult animal subpopulation ranged from 15.0% (1.6–28.5 95% CI; 2014) to 50.6% (38.6–62.6...
95% CI; 2015) in RF and from 22.0% (8.9–35.2 95% CI; 2012) to 64.6% (47.1–82.1 95% CI; 2015) in RD (Additional file 3). The same statistical calculation rates in the young animal subpopulation ranged from 10.8% (2.4–19.2 95% CI; 2014) to 47.6% (28.6–66.7 95% CI; 2015) in juvenile RF and from 11.2% (2.6–19.8 95% CI; 2010) to 50.7% (32.9–68.7 95% CI; 2015) in juvenile RD (Additional file 3). The same statistical analysis between adults and juvenile animal subpopulations (pos.%) identified a strong positive correlation \( r = 0.937, p = 0.0001 \) in the RF population, with an average standard deviation SD of ±5.75%. The same statistical comparison in the RD population showed a moderate correlation \( r = 0.538, p = 0.054 \) between adults and juvenile animals (pos.%,) with an SD of ±4.04%.

The investigation of specific Abs in RF and RD blood sera samples using ELISA during the 2010–2019 ORV spring vaccination periods (Fig. 1b) showed that 1190 RF of 3741 (31.8%) tested (20.3–43.4 95% CI; Additional file 4) and 292 RD of 857 (34.1%) tested (22.5–45.7 95% CI; Additional file 5) sera samples were identified as ELISA-positive (seroconversion \( \geq 0.5 \) EU/mL). Annual immunization rates (pos.%) during the spring vaccination periods (Fig. 1b) ranged from 12.8% (1.5–20.4 95% CI; 2014) to 58.0% (40.8–75.4 95% CI; 2011) in RF and from 19.1% (5.4–32.8 95% CI; 2014) to 64.5% (48.5–80.6 95% CI; 2015) in RD (Additional file 6). In the same ORV autumn periods (Fig. 1b), of the 3520 RF and 1,289 RD sera samples investigated, 1156 RF (31.7%, 21.2–42.1 95% CI Additional file 4) and 447 RD (34.7%, 22.7–46.7 95% CI Additional file 5) were identified as ELISA-positive (seroconversion \( \geq 0.5 \) EU/mL). Annual immunization rates (pos.%) during the autumn vaccination periods ranged from 17.4% (4.3–30.5 95% CI; 2016) to 52.6% (33.3–71.9 95% CI; 2017) in RF (Additional file 6), and from 18.5% (5.1–31.8 95% CI; 2012) to 62.6% (46.3–78.9 95% CI; 2015) in RD populations (Additional file 6). The comparative statistical analysis between spring and autumn vaccination periods identified weak correlations in both (RF and RD) study groups. The correlation coefficient in the RF population was \( r = 0.353 (p = 0.159) \), and the same statistical comparison in the RD population showed an even smaller correlation coefficient \( r = 0.102, p = 0.390 \) between ELISA-positive samples in the spring and autumn vaccination periods.

The investigation of specific Abs in RD and RF blood sera samples using ELISA during the 2010–2019 ORV programme indicated that 44.5% (38.3–50.7 95% CI; Fig. 2a) RD and 43.4% (37.2–49.6 95% CI; Fig. 2b) RF serum samples were negative (<0.125 EU/mL). However, in the same ORV period, 22.6% (20.4–24.8 95% CI; Additional file 4) RF and 17.6% (15.1–20.2 95% CI; Additional file 5) RD serum samples with low specific antibody titres (0.125 < 0.49 EU/mL) were detected, having also been officially classified as negative. ELISA antibody titres greater than 2 EU/mL were detected in 8.6% (6.4–10.8 95% CI; Additional file 4) RF and 13.0% (9.7–16.4 95% CI; Additional file 5) RD serum samples.

A comparative statistical calculation (RF vs. RD) in the period of ORV was performed in two categories of investigation: juvenile/adult subpopulations (Fig. 1a; Additional file 3) and spring/autumn vaccination periods (Fig. 1b; Additional file 6). In the 2010–2019 ORV spring vaccination periods, 3741 of 7261 RF sera samples (51.5%) and 857 of 2146 (39.9%) RD sera samples were ELISA tested. The comparison between RF and RD seropositive sera samples during the spring vaccination period revealed a strong determinate linear correlation \( r = 0.864, p = 0.0006 \), with an SD of ±9.53%. In contrast to the spring vaccination periods, a weak
During the ORV programme period, 87.2% (with 34.9% positive) of ELISA-tested RF and 83.7% (with 35.6% positive) of RD sera samples were collected from adult animals. The comparison between RF and RD positive samples in the adult animal subpopulation (Additional file 3) identified a weak linear correlation ($r=0.299, p=0.200$), with an SD of ±1.27%. In contrast to adult animals, a reasonably strong linear correlation ($r=0.603, p=0.032$) was observed between RF and RD juvenile subpopulations, with an SD of ±4.03%.

During the 2016–2019 ORV period, 3,346 of tested 7,261 RF serum samples and 809 of tested 2,146 RD serum samples were collected in the vaccination protection zone (Fig. 3). The investigation of RF annual immunization rates (pos.%) during the different years of vaccination periods showed that the highest seroconversion was found in 2017 (44.5%) and the smallest in 2018 (29.8%). The same investigation of sera samples from vaccination protection zone in RD population identified the highest seroconversion in 2016 (38.5%) and the lowest in 2019 (21.8%). Comparative analysis of seroconversion
rates between the samples collected during 2016–2019 period in the vaccination protection zone and the sample collected in the rest of the territory of Lithuania identified a statistically minute difference between the seroconversion averages in these regions. Annual immunization rates (pos.%) in RF sera samples from the vaccination protection zone was 37.5% vs seroconversion of 31.3% in sera samples from other territories of Lithuania. The same comparative analysis in RD population revealed annual immunization rates of 30.7% (protection zone) vs 28.6% (other territories). Comparative study of seroconversion rates (pos.%) between the vaccination protection zone and the rest of Lithuanian territory showed that the mean of seroconversion rates in RF sera samples from vaccination zone were significantly ($p = 0.046$) higher at 7.5%.

Epidemiological data (one of the main effectiveness criteria) during the implementation of the ORV program are very important for evaluating of the ORV program. In Lithuania, 14 rabies-positive cases (Rab. pos.) were detected in the RF population and 13 in the RD population in 2010, while in 2013 and 2014, no rabies-positive cases were detected (Fig. 4). Since 2015 (confirmed rabies-free status), one positive case of rabies per year (2016–2018) was detected in RF population in the buffer vaccination zone. Therefore, such rabies epidemiological data confirm the efficacy of Lithuanian ORV during the study period.

Discussion

In the last three decades, the implementation of ORV programmes in 24 countries has led to eradication of fox-mediated rabies from large areas of western and central Europe [26, 31, 32]. ELISA serological testing of vaccinated wild animals has been widely performed throughout Europe, especially for evaluating ORV efficacy in vaccinated fox populations [33]. ELISA has been used to optimize common test protocols between reference laboratories in different countries (the first inter-laboratory testing was conducted in 2003) for comparative analysis of seroprevalence results [18]. In 2010, 73% of national rabies reference laboratories in the EU used commercially available ELISA kits to test ORV vaccination effectiveness, with 18% and 9% of reference laboratories using RFFIT and FAVN tests respectively [29, 34].

For a long time in many ORV programs, the target wildlife for vaccination has been RF, however, in the last 30–35 years in northern Europe (including Lithuania) RD has become an important co-factor in the transmission of rabies. These two species are particularly important in the comparative analysis and interpretation of ORV seroconversion rate in Lithuanian wildlife populations. In the 2010–2019 ORV period in Lithuania the comparative seroconversion analysis between RF and RD was performed, because these two species have “slightly” different ecological cycles in their identical area of habitation (subsequent reproductive cycle of RD). The data of seroconversion in spring/autumn ORV therefore was of particularly importance (strong correlation in the seropositive % between RF and RD during the spring vaccinations). The seroconversion in adult and juvenile age groups was analyzed because the formation of long-term population immune status (including multiple vaccinations) as a consequence of ORV can only be assessed relatively, as the age-related structural indicators of the target populations can vary greatly long term (strong correlation between the seropositive % in RF adult/juvenile animal subpopulations). The statistical investigation of ELISA-positive (seroconversion ≥ 0.5 EU/mL) sera samples in juvenile subpopulations (RD vs RF) showed that the variations in seroconversion rates (pos.%) during the analytic period were similar in both species (10.8–47.6% RF and 11.2–50.7% RD). However, during the last 3 years of the ORV program, seroconversion in the RD juvenile population was significantly higher compared to RF (42.3% RD vs 35.2% RF). Juveniles (cubs) of both species are not the targets of spring ORV (March–May). The priority of the spring ORV is immunization (“booster” vaccination) of young animal (12–16 months old) subpopulations that may have been vaccinated in the last year autumn (October–December) ORV campaigns.

During the ORV study period the average seroprevalence rate (positive% ≥ 0.5 EU/mL) was approximately 33% in RF and 38% in RD populations in all age groups. At the same time, large variations in seroconversion levels (seropositive %) were observed in Lithuania; of ELISA-positive samples, 28% and 33% were identified in 2010 for RF and RD, respectively (four years after the ORV commenced). However, in 2015 there were 50% positive samples in RF and 64% in RD sera. It should be noted that similar variations have been found in the seroprevalence rates of target red fox and raccoon dog sera samples in the other Baltic countries, with the largest seropositive sera samples observed in Latvia (73%—autumn 2010) and the smallest in Estonia (30%—autumn 2011) [4]. Possible reasons for these seroprevalence results can be associated with the poor quality of the sera samples collected under field conditions, ELISA sensitivity as well as the ecological factors of target wild animals.

Analysis of long-term national ORV programmes under field conditions showed that the overall bait consumption (TTC marker) was 80%, while the seroprevalence rate was approximately 50% [3, 26, 29]. A relatively large discrepancy between bait uptake and seroprevalence was attributed to a variation in the sensitivity of the commercially available ELISA kits due to
the poor quality of field samples (haemolysis, bacterial contamination) compared with blood samples from experimentally vaccinated RF and RD [26, 35]. Many studies have identified the influence of poor-quality serum samples on ELISA quality. One possible reason might be associated with partial denaturation (degradation) of IgG heavy chains in poor-quality tissue fluids and heavily haemolyzed blood samples collected post-mortem in the field [6, 35, 36]. During the investigation of Lithuania’s ORV programme, 25–40% (depending on the year, hunting period, sample collection and transportation conditions, species etc.) of samples were highly haemolyzed. Some of them (10–25%) could be categorized as “body or tissue fluids” and theoretically would not qualify for testing by the spectrophotometrical optical density ELISA method. However, all the collected haemolyzed sera samples were investigated and approximately 20% of them were identified as positive (with RV Abs titers of 0.5 ≤ 2 EU/mL), and 12–15% were identified as negative, but with low titers (0.125 < 0.49 EU/mL). The high seroconversion (with RV Abs titres of < 2 EU/mL) were not detected in hemolyzed serum samples. A certain degree of variability in the quality of sera should be expected under field conditions. Any test must therefore be robust enough to avoid the false positive/negative results due to serum quality [35].

Similar differences in ELISA sensitivity have been determined by comparing Bio-Rad ELISA Platelia™ Rabies II kit (which was used during the 2010–2019 ORV program in Lithuania) and another commercially available ELISA kit (BioPro ELISA kit) in animal blood sera samples. The results showed greater sensitivity in the BioPro ELISA kit (83.2%) compared with the Bio-Rad Platelia™ Rabies II kit (66.4%) [37]. The observed differences may be related to the lower sensitivity of the Platelia Rabies II kit, previously reported in field-collected fox sera [35], and can be associated with difficulties in interpreting oral vaccination data [21]. However, in Latvia, where both ELISA kits (Bio-Rad and BioPro) have been used to test seroprevalence during the ORV programme in wildlife, the investigation of kit sensitivity identified a high degree of differences of Abs titres. BioPro ELISA results showed lower seroconversion rates than the Bio-Rad ELISA kit, therefore the results of that study were completely different (converse) to the data provided by other studies [4, 21, 37]. These results may have been influenced by the use of a lower positive cut-off value concentration (0.125 EU/mL) than the recommended (0.5 EU/mL) cut-off value concentration of Abs titres in the Bio-Rad kit, which was probably too restrictive. In fact, using a threshold level of 0.2 and 0.3 EU/mL led to the observation of a significant increase in ELISA sensitivity (92.68% and 86.87% respectively) and better correlation with FAVN [9]. Therefore, the different commercial ELISA kits (Bio-Rad/ BioPro) potentially initiate different seropositive results not only due to the biochemical properties of the rabies glycoprotein (purity/degradation), but also due to different optical density evaluation criteria. The use of different ELISA kits may influence the objective result (seropositive %), their interpretation and as a consequence—ORV efficacy in analytic/prognostic models.

There are various different opinions about the minimum reliable RV-specific Abs titres in vaccinated wildlife that would suggest a minimal protective immune response in a susceptible population. Understandably, the Abs level is one of the main indicators of resistance to infection, however the statistical evaluation of seroconversion in different biological models is not absolutely correct, i.e., some animals with “sufficient” or even “high” Abs titres may potentially become infected with RV and some seronegative individuals might survive after experimental virus infection [38–41]. During the time of investigation of the Lithuanian ORV, more than 1,100 RF and 400 RD sera samples were identified with low 0.125 < 0.49 EU/mL Abs titres (positive, but insufficient serological response), and were qualified as Bio-Rad ELISA-negative (<0.5 EU/mL). In the spring ORV periods, 23% RF and 18% RD sera samples with low Abs titres were identified. Similar results were found during the autumn ORV periods, with 21% RF and 17% RD sera samples with 0.125 < 0.49 EU/mL Abs titres. The same proportion with 1–2% variation of ELISA-negative samples was acquired in juvenile/adult target animal subpopulations. About 10% of ELISA seronegative samples had antibody titers of 0.4–0.49 EU/mL, therefore positive seroconversion participated directly in the formation of overall immune status of the population. According to the age statistic of hunted animals, 8–10% of older (>5 years) animals are hunted in Lithuania. During the different Lithuanian ORV periods, 70–80% of in field-collected samples subjected to ELISA were from animals 1 to 3 years of age. Therefore the formation of long-term immune status of the population (including the multiple vaccination) as a consequence of ORV can only be assessed relatively, as the age-related structural indicators of the target populations can vary greatly on a long-term basis. Under the influence of different ecological/epidemiological/reproductive factors, the age-related structural change of the RF/RD populations can reach 50% and more in different time periods. Thus, the 35% statistical average of ORV seroprevalence status in susceptible animal populations may already be a “constant-attractive” factor in epidemiological control. Most discrepancies were observed in serum samples with antibody titres close to the ELISA
threshold value (0.5 EU/mL). Serum samples with antibody titres between 0.5 and 1 EU/mL were found to have low ELISA sensitivity (50%), but the sensitivity was significantly increased (up to 92.8%) in serum samples with antibody titres up to 5 EU/mL. Studies have shown that the sensitivity of the Bio-Rad ELISA for fox serum samples from ORV regions is significantly lower (32.4%) than RFFIT [35]. In addition, similar tests in EU-RL in Nancy[36] showed that ELISA antibody titres (EU/mL) in control samples were two to five times lower than classical virus-neutralisation assays (SNT-serum neutralization test). Bio-Rad ELISA results only correlate reasonably well with RFFIT when the expected antibody titres are greater than 1.0 IU/mL. However, when the expected antibody titre is lower, its sensitivity is completely inadequate. Therefore, the use of Bio-Rad ELISA should rely on its specificity to identify seronegative specimens, since its sensitivity in determining antibody titres in vaccinated wildlife animals should be deemed unsatisfactory [39]. Therefore, the lack of sensitivity of the Bio-Rad PlateliaTM Rabies II kit and a certain degree of variability in the quality of field sera samples could be a key point for identifying threshold seroconversion in target wildlife during an ORV programmes. Consequently, the evaluation of the Lithuanian ORV programme in low immunogenic serum samples and predictably weak (lower than 50%) ELISA kit sensitivity can influence the interpretation of the seroprevalence rate in target populations.

Conclusions
The long-term ORV programme has been an effective tool in both RF and RD populations in Lithuania – only three rabies cases identified in buffer zones since 2015 (Fig. 3). 14–29% of RF and 7–25% of RD serum samples were identified as ELISA-negative, but with low 0.125<0.49 EU/mL. Abs titres. Comparative serological data indicate a sensitivity less than 50% of ELISA tests in poor quality serum samples with low antibody titers, therefore it can be expected that the part of Lithuanian samples collected from vaccination areas in the field and tested by ELISA could be considered negative due to their poor biological quality. The real seroconversion percentage in susceptible animal populations could be higher: RF and RD with low ELISA Abs titres (specifically 10% serum samples within 0.4<0.49 EU/mL) likely participated in the formation of the overall immune status of the population. Including target animals with low Abs could directly influence the interpretation of oral vaccination efficacy.

Abbreviations
95% CI: 95% Confidence interval; EFSA: European Food Safety Authority; ELISA: Enzyme-linked immunosorbent assay; EU/mL: Equivalent units per millilitre; FAVN: Fluorescent antibody virus neutralization test; FFU: Focus forming units; FUCHSORAL (IDT Biologika GmbH, Germany): Live attenuated RV vaccine, LYSVULPEN (Bioveta A.S., Czech Republic): Live attenuated RV vaccine; M: Mean values; NFVRAI: National Food and Veterinary Risk Assessment Institute of Lithuania; OD: Optical density; ORV: Oral rabies vaccination; p: Confidence factor; PC: Calibrated positive controls; r: Spearman correlation coefficient; RD: Raccoon dog (Nyctereutes procyonoides); RF: Red fox (Vulpes vulpes); RFFIT: Rapid fluorescent focus inhibition test; RV: Rabies virus; S1–S6: Quantitative standards; SD: Average standard deviation; SNT: Serum neutralization test; TCI: Tissue culture infective dose; WHO: World Health Organization.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13028-021-00577-z.

Acknowledgements
We thank the local hunters and the laboratory technicians from Virology Department at the National Food and Veterinary Risk Assessment Institute for their collaboration.

Prior publication
Data have not been published previously.

Authors’ contributions
DZ and li presented the idea of the study, planned and designed the study. DZ, JM, JK performed the literature review. GP, EJ contacted and got the agreements with the hunters, coordinated and participated in the sampling. Ll, JMJ and JK were responsible for the laboratory work (serological tests) and preliminary data analysis. AP, DZ and AS performed the statistical analyses, drafted and revised the manuscript. Ll, JG, DZ participated in the design and interpretation of full papers and in the acquisition of data, and drafted and revised the manuscript. DZ prepared the manuscript. All authors participated in the subsequent discussions and revisions of the entire text. All authors read and approved the final manuscript.

Funding
This research received no external funding.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate
This study did not require official or institutional ethical approval as no animals were hunted for the purpose of this study. Certified hunters shot the red foxes and raccoon dogs during the official hunting seasons, and the samples were collected post mortem as part of a national ORV effectiveness study program. The data were handled confidentially.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1. Lithuanian University of Health Sciences, Institute of Microbiology and Virology, Lithuania, Tėbės str. 18, 47181 Kaunas, Lithuania. 2. National Food and Veterinary Risk Assessment Institute, National Food and Veterinary Risk Assessment Institute, J. Kairiukštio str. 10, 08409 Vilnius, Lithuania.

Received: 18 September 2020  Accepted: 8 March 2021
Published online: 20 March 2021

References
1. Singer A, Kauhala K, Holmala K, Smith GC. Rabies risk in raccoon dogs and foxes. Towards the Elimination of Rabies in Eurasia. Dev Biol Basel. 2008;313:21–22.
2. Niin E, Laine M, Guiot AL, Demerson JM, Cliquet F. Rabies in Estonia: situation before and after the first campaigns of oral vaccination of wildlife with SAG2 vaccine bait. Vaccine. 2008;26:3556–65. https://doi.org/10.1016/j.vaccine.2008.04.056 (PMID:18524435).
3. Olsevskis E, Liepins E, Lamberga K, Rodze I. Efficacy of the first large-scale rabies oral vaccination campaigns in Latvia during Annual 17th International Scientific Conference Proceedings “Research for rural development.” Jelgava, Latvia. 2005;2011:166–72.
4. Robardet E, Picard-Meyer E, Dobroštana M, Jaceviciene I, Mähar K, et al. Rabies in the Baltic States: Decoding a Process of Control and Elimination. PLoS Negl Trop Dis. 2016;10(2): e0004432. https://doi.org/10.1371/journal.pntd.0004432.
5. EC (European Commission). Guidelines to design an EU co-financed programme on eradication and control of rabies in wildlife SANTE(2010)215. 2015;1–18. http://ec.europa.eu/dgs/health_food-safety/funding/cf/docs/animal_vet_progs_guidance_rabies.pdf.
6. De Benedictis P, Mancin M, Cattoli G, Capua I, Terrregino C. Serological methods used for rabies post vaccination surveys: an analysis. Vaccine. 2012;30:5611–5.
7. Cliquet F, Freuling C, Smreczak M, van der Poel WHM, Horton D, Fooks AR, Robardet E, et al. Development of harmonised schemes for monitoring and reporting of rabies in animals in the European Union. EFSA Sci Rep. 2010;6:101.
8. Johnson N, Cunningham AF, Fooks AR. The immune response to rabies virus infection and vaccination. Vaccine. 2010;28:3896–901.
9. Wasniewski M, Labbe A, Tribout L, Rieder J, Labadie A, Schereffer JL, Cliquet F. Evaluation of a rabies ELISA as an alternative method to seroneutralization tests in the context of international trade of domestic carnivores. J Virol Methods. 2014;195:211–20.
10. Aubert MFA. Can vaccination validated by the titration of rabies antibodies in serum of cats and dogs be an alternative to quarantine measures? Abst Hyg Commun Diss. 1993:681.
11. Brown LJ, Rosatte RC, Fehliner-Gardiner C, Knovles MK, Bachmann P, Davies JC, et al. Immunogenicity and efficacy of two rabies vaccines in wild-captured, captive raccoons. J Wildl Dis. 2011;47:182–94.
12. WHO. WHO expert consultation on rabies. Second report. Geneva: World Health Organization; 2013.
13. OIE (Office International des Epizooties). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals: Mammals, Birds and Bees. Rabies, 2014;1–26.
14. Cliquet F, Barrat J. Rabies. In: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (Mammals, Birds and Bees). Office International des Epizooties, Paris. 2008;304–22.
15. Pastoret PP, van Gucht S, Brocher B. Eradicating rabies at source. Revue Scientifique Et Technique. Office International des Epizooties. 2014;43:509–19.
16. Cliquet F, Aubert M, Sagne L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralizing antibody. J Immunol Methods. 1998;212:79–87.
17. Smith JS, Yager PA, Baer GM. A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ. 1973;68:535–41.
18. Cliquet F, Müller T, Mutinelli F, Gerontutti S, Brocher B, Selhorst T, et al. Standardisation and establishment of a rabies ELISA test in European laboratories for assessing the efficacy of oral fox vaccination campaigns. Vaccine. 2003;21:2986–93.
19. Servat A, Wasniewski M, Cliquet F. Tools for rabies serology to monitor the effectiveness of rabies vaccination in domestic and wild carnivores. Dev Biol Basel. 2006;125:91–4.
20. Cliquet F, Sagne L, Schereffer JL, Aubert MF. ELISA test for rabies antibody titration in orally vaccinated foxes sampled in the fields. Vaccine. 2000;18:3272–9.
21. Wasniewski M, Guiot AL, Schereffer JL, Tribout L, Mähar K, Cliquet F. Evaluation of an ELISA to detect rabies antibodies in orally-vaccinated foxes and raccoon dogs sampled in the field. J Virol Methods. 2013;187:264–70.
22. Servat A, Labadie A, Hamen A, Boue F, Cliquet F. Inter-laboratory trial to evaluate the reproducibility of a new ELISA to detect rabies antibodies in vaccinated domestic and wild carnivores. Biologicals. 2008;36:19–26.
23. Vengust G, Hostnik P, Cilensek P, Malovrh T. Presence of antibodies against rabies in wild boars. Acta Vet Hung. 2011;59:149–54.
24. Servat A, Feys-Saguuet M, Blanchard I, Morize JL, Schereffer JL, Boue F, Cliquet F. A quantitative indirect ELISA to monitor the effectiveness of rabies vaccination in domestic and wild carnivores. J Immunol Methods. 2007;318:1–10.
25. Breitenmoser U, Müller U, Kappeler A, Zanoni R. Die Endphase der Tollwut in der Schweiz. Schweiz Arch Tierhef. 2000;147:447–53.
26. Cliquet F, Robardet E, Murt K, Laine M, Peik K, Picard-Meyer E, et al. Eliminating rabies in Estonia. PIOS Negl Trop Dis. 2012;6:1–17.
27. Mulatti P, Bonfanti L, Patregnani T, Lorenzetto M, Ferre N, Gagliasso L, et al. 2008–2011 sylvatic rabies epidemic in Italy: challenges and experiences. Pathog Glob Health. 2013;107:346–53.
28. WHO. WHO Expert Consultation on Rabies. Geneva: World Health Organization; 2005. p. 121.
29. EFSA. AHAW Panel. Update on oral vaccination of foxes and raccoon dogs against rabies. Scientific Panel on Animal Health and Welfare (AHAW). EFSA J. 2015;13:70–79.
30. OIE (Office International des Epizooties), Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (Mammals, Birds and Bees). OIE, Paris, 2012.
31. Muster T, Bátza HJ, Freuling C, Klie sm A, Klie sm J, Heuser R, et al. Elimination of rabies transmission in domestic cats in Germany using oral vaccination of foxes. Berl Munch Tierärztliche Wochenschr. 2012;125:178–90.
32. Freuling CM, Hampson K, Selhorst T, Schroder R, Meslin FX, Mettenleiter TC, et al. The elimination of fox rabies from Europe: determinants of success and lessons for the future. Phil Trans R Soc B. 2013;368:20120142. https://doi.org/10.1098/rstb.2012.0142.
33. Mozis M, Korytar P, Jerg S. Development and validation of ELISA test for detection of rabies anti-glycoprotein antibodies. In: International Conference on Rabies in the Americas (RITA XIX), Atlanta, 2008;48–9.
34. Robardet E, Cliquet F. Review of the analysis related to rabies diagnosis and follow-up of oral vaccination performed in NRLs in the EU, 2010. Rabies Bulletin Europe. 2011;35:11–4.
35. Knoop EV, Freuling CM, Kliemt J, Selhorst T, Conraths FJ, Müller T. Evaluation of a commercial rabies ELISA as a replacement for serum neutralization assays as part of the pet travel scheme and oral vaccination campaigns of foxes. Berl Munch Tierärztliche Wochenschr. 2010;123:278–85.
36. Wasniewski M, Cliquet F. Technical report on several studies performed by Afssa Nancy laboratory on the Platelia Rabies II kit designed by Biorad. Technical report by AFSSA. 2008; Nancy, France, 1–23.
37. Wasniewski M, Cliquet F. Evaluation of ELISA for detection of rabies antibodies in domestic carnivores. J Virol Methods. 2012;179:166–75.
38. Moore SM, Ricke TA, Davis RD, Briggs DJ. The influence of homologous vs heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays. Biologicals. 2005;33:269–76.
39. Moore SM, Gilbert A, Vos A, Freuling CM, Ellis C, Kliemt J, et al. Rabies virus antibodies from oral vaccination as a correlate of protection against lethal infection in wildlife. Trop Med Infect Dis. 2017;2:31. https://doi.org/10.3390/tropicalmed2030031.
40. Moore SM, Hanlon CA. Rabies-specific antibodies: Measuring surrogates of protection against a fatal disease. PLoS Negl Trop Dis. 2010;4:e595. https://doi.org/10.1371/journal.pntd.0000595.
41. Brown LJ, Rosatte RC, Fehlner-Gardiner C, Taylor JS, Davies JC, Donovan D. Immune response and protection in raccoons (Procyon lotor) following consumption of baits containing ONRAB®, a human adenovirus rabies glycoprotein recombinant vaccine. J Wildl Dis. 2012;48:1010–20.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.